Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Prostaglandin F2α (PGF2α) is a naturally occurring prostaglandin that is widely distributed and found in many species. It is known for its ability to cause contraction of vascular, bronchial, intestinal, and myometrial smooth muscle, as well as its potent luteolytic activity. PGF2α exerts its receptor-mediated physiological activity at concentrations of 50-100 nM, with maximal ovine myometrial contraction achievable at 125 nM in vitro. It is closely related to Prostaglandin E2 (PGE2), as both are biosynthesized from the same precursors, and PGF2α is the synthetic reduction product of PGE2.

551-11-1 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 551-11-1 Structure
  • Basic information

    1. Product Name: Prostaglandin F2a
    2. Synonyms: PROSTAGLANDIN F2ALPHA;PGF2ALPHA;9ALPHA,11ALPHA,15S-TRIHYDROXY-PROSTA-5Z,13E-DIEN-1-OIC ACID;DINOPROST;(5z,9alpha,11alpha,13e,15s)-9,11,15-trihydroxyprosta-3,13-dien-1-oicacid;2beta(s*,e),3alpha,5alpha))-alpha(z;5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-7-(l-5-heptenoicaci;7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-5-heptenoicaci
    3. CAS NO:551-11-1
    4. Molecular Formula: C20H34O5
    5. Molecular Weight: 354.48
    6. EINECS: N/A
    7. Product Categories: Prostaglandins;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
    8. Mol File: 551-11-1.mol
  • Chemical Properties

    1. Melting Point: 25-35°
    2. Boiling Point: 407.69°C (rough estimate)
    3. Flash Point: 289 °C
    4. Appearance: White to off-white crystalline solid
    5. Density: 1.0458 (rough estimate)
    6. Vapor Pressure: 1.71E-13mmHg at 25°C
    7. Refractive Index: 1.6120 (estimate)
    8. Storage Temp.: N/A
    9. Solubility: N/A
    10. PKA: pKa 4.90(H2O,t=25±2,I=0.0,c<0.01,N2) (Uncertain)
    11. CAS DataBase Reference: Prostaglandin F2a(CAS DataBase Reference)
    12. NIST Chemistry Reference: Prostaglandin F2a(551-11-1)
    13. EPA Substance Registry System: Prostaglandin F2a(551-11-1)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 551-11-1(Hazardous Substances Data)

551-11-1 Usage

Uses

Used in Pharmaceutical Industry:
Prostaglandin F2α is used as a pharmaceutical agent for inducing labor in obstetrics. It is particularly effective due to its ability to cause contraction of myometrial smooth muscle, which helps initiate and maintain labor.
Used in Veterinary Medicine:
In veterinary medicine, PGF2α is used as a luteolytic agent to control the estrous cycle in animals, such as cows and sheep. Its potent luteolytic activity helps regulate reproductive processes and improve the efficiency of breeding programs.
Used in Research:
Prostaglandin F2α is also used in research settings to study the physiological effects of prostaglandins on various tissues and organs, including their role in inflammation, pain, and other biological processes. This helps scientists better understand the mechanisms of action and potential therapeutic applications of prostaglandins.

History

Prostaglandins (PGs) are a class of important endogenous products with a wide range of physiological activities. PGs were first discovered and named by American scholar Von Eluer in 1930. In 1962, Bergstorm extracted two pure PGs (PGF1 and PGF2) and determined their chemical structures. In 1969, Willis first proposed that PGs are an inflammatory mediator in the body. Subsequently, various physiological and pharmacological activities of PGs have been intensively studied.

Pharmacokinetics

Dinoprost is a natural prostaglandin F2α (PGF2α), which can directly act on the myometrium, stimulate the pregnant uterus to contract the uterine muscle, and can soften and dilate the cervix, so it can be used for induced abortion and late labor induction. However, due to the instability of dinoprost at room temperature, inconvenient storage and transportation, complex synthesis process and high cost, the application of dinoprost is difficult to popularize.

Safety Profile

Poison by subcutaneous, intravenous, and intramuscular routes. Moderately toxic by ingestion. Human and experimental teratogenic and experimental reproductive effects. Human reproductive effects by subcutaneous, intravenous, intramuscular, intraperitoneal, intravaginal, and intraplacental routes: postpartum depression and other maternal effects, abortion, and changes in measures of ferulity. Human teratogenic effects by intraplacental route: extra embryonic structures. Human systemic effects by intravenous route: hypermoulity, diarrhea, nausea or vomiting. Human mutation data reported. When heated to decomposition it emits acrid smoke and fumes

Check Digit Verification of cas no

The CAS Registry Mumber 551-11-1 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,5 and 1 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 551-11:
(5*5)+(4*5)+(3*1)+(2*1)+(1*1)=51
51 % 10 = 1
So 551-11-1 is a valid CAS Registry Number.
InChI:InChI=1/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/t15-,16+,17+,18-,19+/m0/s1

551-11-1 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (P1885)  Prostaglandin F  >95.0%(T)

  • 551-11-1

  • 1mg

  • 490.00CNY

  • Detail
  • TCI America

  • (P1885)  Prostaglandin F  >95.0%(T)

  • 551-11-1

  • 10mg

  • 3,450.00CNY

  • Detail

551-11-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name prostaglandin F2α

1.2 Other means of identification

Product number -
Other names glandin

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:551-11-1 SDS

551-11-1Synthetic route

(Z)-7-((1R,2R,3R,5S)-3-(tert-butyldimethylsilyloxy)-2-((S,E)-3-(tert-butyldimethylsilyloxy)oct-1-enyl)-5-(triethylsilyloxy)cyclopentyl)hept-5-enoic acid

(Z)-7-((1R,2R,3R,5S)-3-(tert-butyldimethylsilyloxy)-2-((S,E)-3-(tert-butyldimethylsilyloxy)oct-1-enyl)-5-(triethylsilyloxy)cyclopentyl)hept-5-enoic acid

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
With hydrogenchloride In water; acetone at 20℃; for 0.333333h; Inert atmosphere;99%
methyl (5Z)-7-{(1R,2R,3R,5R)-5-acetoxy-3-hydroxy-2-[(1E,3S)-3-hydroxy-1-octenyl]cyclopentyl}-5-heptenoate
55022-57-6

methyl (5Z)-7-{(1R,2R,3R,5R)-5-acetoxy-3-hydroxy-2-[(1E,3S)-3-hydroxy-1-octenyl]cyclopentyl}-5-heptenoate

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
With sodium hydroxide In tetrahydrofuran; methanol Ambient temperature;95%
With sodium hydroxide In tetrahydrofuran; methanol at 20℃; for 2h;
(+)-prostaglandin F2α
33854-16-9

(+)-prostaglandin F2α

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
With water In tert-butyl methyl ether at 35℃; for 18h; Enzymatic reaction;90%
base hydrolysis; Yield given;
(Z)-7-((1R,2R,3R,5S)-3-[(tert-butyldimethylsilanyl)oxy]-2-{(S,E)-3-[(tert-butyldimethylsilanyl)oxy]oct-1-en-1-yl}-5-hydroxycyclopentyl)hept-5-enoic acid
1239683-12-5

(Z)-7-((1R,2R,3R,5S)-3-[(tert-butyldimethylsilanyl)oxy]-2-{(S,E)-3-[(tert-butyldimethylsilanyl)oxy]oct-1-en-1-yl}-5-hydroxycyclopentyl)hept-5-enoic acid

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
With hydrogen fluoride; water In acetonitrile at 20℃; for 7h; stereoselective reaction;90%
With hydrogenchloride In tetrahydrofuran; water at -78 - 20℃; for 6h;89%
With hydrogenchloride In tetrahydrofuran; water at 20℃; for 6h; Inert atmosphere;89%
(Z)-7-[(1R,2R,3R,5S)-3-Benzyloxy-2-((E)-(S)-3-benzyloxy-oct-1-enyl)-5-hydroxy-cyclopentyl]-hept-5-enoic acid
145313-85-5

(Z)-7-[(1R,2R,3R,5S)-3-Benzyloxy-2-((E)-(S)-3-benzyloxy-oct-1-enyl)-5-hydroxy-cyclopentyl]-hept-5-enoic acid

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
With ammonia; sodium75%
5-hexenoic acid
1577-22-6

5-hexenoic acid

C16H28O3

C16H28O3

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
With (Z)-2-Butene; C37H40Cl2N2ORuS2 In tetrahydrofuran at 22℃; under 7 Torr; Pressure; Inert atmosphere; Glovebox; Sealed tube;75%
(3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol
51388-75-1, 59829-49-1, 59829-50-4, 59829-51-5, 59829-52-6, 85550-76-1, 85550-82-9, 136235-23-9, 136235-24-0

(3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol

(4-carboxybutyl)triphenylphosphonium bromide
17814-85-6

(4-carboxybutyl)triphenylphosphonium bromide

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
With potassium tert-butylate In tetrahydrofuran at 20℃; Wittig Olefination;55%
Stage #1: (4-carboxybutyl)triphenylphosphonium bromide With potassium tert-butylate In tetrahydrofuran at 0℃; for 0.666667h; Wittig Olefination; Schlenk technique; Inert atmosphere;
Stage #2: (3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol In tetrahydrofuran at 20℃; for 1h; Wittig Olefination; Schlenk technique; Inert atmosphere;
152 mg
Stage #1: (4-carboxybutyl)triphenylphosphonium bromide With potassium tert-butylate In tetrahydrofuran at 0℃; for 0.666667h; Inert atmosphere;
Stage #2: (3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol In tetrahydrofuran at 0 - 20℃; for 1h; Inert atmosphere;
152 mg
Stage #1: (4-carboxybutyl)triphenylphosphonium bromide With potassium tert-butylate In tetrahydrofuran at 0℃; for 0.666667h; Wittig Olefination; Schlenk technique; Inert atmosphere;
Stage #2: (3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol In tetrahydrofuran at 0 - 20℃; for 1.5h; Wittig Olefination; Schlenk technique; Inert atmosphere;
24.8 mg
Stage #1: (4-carboxybutyl)triphenylphosphonium bromide With potassium tert-butylate In tetrahydrofuran at 0℃; for 0.666667h; Inert atmosphere;
Stage #2: (3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol In tetrahydrofuran at 0 - 20℃; for 2h; Inert atmosphere;
70 mg
(3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol
51388-75-1, 59829-49-1, 59829-50-4, 59829-51-5, 59829-52-6, 85550-76-1, 85550-82-9, 136235-23-9, 136235-24-0

(3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol

(4-carboxybutylene)triphenylphosphorane
39968-97-3

(4-carboxybutylene)triphenylphosphorane

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
Stage #1: (4-carboxybutylene)triphenylphosphorane With potassium tert-butylate In tetrahydrofuran at 0 - 5℃; for 0.666667h; Inert atmosphere;
Stage #2: (3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol In tetrahydrofuran at 20℃; for 1h;
54%
(3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol
51388-75-1, 59829-49-1, 59829-50-4, 59829-51-5, 59829-52-6, 85550-76-1, 85550-82-9, 136235-23-9, 136235-24-0

(3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol

4-carboxybutyliden triphenylphosphorane sodium
41723-91-5

4-carboxybutyliden triphenylphosphorane sodium

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
53%
prostaglandin G2

prostaglandin G2

A

dinoprost
551-11-1

dinoprost

B

15-Keto PGF2a
35850-13-6

15-Keto PGF2a

C

15-OOH-PGF2α

15-OOH-PGF2α

Conditions
ConditionsYield
In water for 0.166667h; Gersemia fruticosa preparation, pH 8.5;A 20%
B 20%
C 20%
dinoprostone
363-24-6

dinoprostone

A

dinoprost
551-11-1

dinoprost

B

Prostaglandin F2b
4510-16-1

Prostaglandin F2b

Conditions
ConditionsYield
With ammonia; lithium In tetrahydrofuran Product distribution;A 8 % Chromat.
B 92 % Chromat.
(3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol
51388-75-1, 59829-49-1, 59829-50-4, 59829-51-5, 59829-52-6, 85550-76-1, 85550-82-9, 136235-23-9, 136235-24-0

(3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol

5-(Triphenyl-λ5-phosphanylidene)-pentanoic acid anion
42186-61-8

5-(Triphenyl-λ5-phosphanylidene)-pentanoic acid anion

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
Yield given;
(4-carboxybutyl)triphenylphosphonium bromide

(4-carboxybutyl)triphenylphosphonium bromide

(3aR,4R,5R,6aS)-5-Trimethylsilanyloxy-4-((E)-(S)-3-trimethylsilanyloxy-oct-1-enyl)-hexahydro-cyclopenta[b]furan-2-ol
131877-95-7

(3aR,4R,5R,6aS)-5-Trimethylsilanyloxy-4-((E)-(S)-3-trimethylsilanyloxy-oct-1-enyl)-hexahydro-cyclopenta[b]furan-2-ol

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
Yield given. Multistep reaction;
4-carboxybutyliden triphenylphosphorane sodium
41723-91-5

4-carboxybutyliden triphenylphosphorane sodium

(3aR,4R,5R,6aS)-4-((E)-(S)-3-Hydroxy-oct-1-enyl)-5-(tetrahydro-pyran-2-yloxy)-hexahydro-cyclopenta[b]furan-2-ol
120445-30-9

(3aR,4R,5R,6aS)-4-((E)-(S)-3-Hydroxy-oct-1-enyl)-5-(tetrahydro-pyran-2-yloxy)-hexahydro-cyclopenta[b]furan-2-ol

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
With acetic acid Yield given. Multistep reaction;
methyl 11α-acetoxy-9α,15(S)-dihydroxy-5-cis-13-transprostadienoate
74728-06-6

methyl 11α-acetoxy-9α,15(S)-dihydroxy-5-cis-13-transprostadienoate

dinoprost
551-11-1

dinoprost

(Z)-7-{(1R,2R,3R,5S)-2-[(E)-(S)-3-(tert-Butyl-dimethyl-silanyloxy)-oct-1-enyl]-3,5-dihydroxy-cyclopentyl}-hept-5-enoic acid anion

(Z)-7-{(1R,2R,3R,5S)-2-[(E)-(S)-3-(tert-Butyl-dimethyl-silanyloxy)-oct-1-enyl]-3,5-dihydroxy-cyclopentyl}-hept-5-enoic acid anion

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
With water; hydrogen cation Yield given;
15-(t-butyldiphenylsilyl) PGF2α
118908-08-0

15-(t-butyldiphenylsilyl) PGF2α

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
With tetrabutyl ammonium fluoride In tetrahydrofuran for 48h; Yield given;
prostaglandin G2

prostaglandin G2

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
With tin(ll) chloride
all cis 5,8,11,14-eicosatetraenoic acid
506-32-1

all cis 5,8,11,14-eicosatetraenoic acid

A

prostaglandin D2
41598-07-6

prostaglandin D2

B

dinoprostone
363-24-6

dinoprostone

C

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
With Tris HCl buffer; GLUTATHIONE; prostaglandin synthetase; L-epinephrine at 37℃; for 0.0833333h; Product distribution; var. prostaglandin synthetase source (animal and tissue); var. conc. of reactants; var. time;
all cis 5,8,11,14-eicosatetraenoic acid
506-32-1

all cis 5,8,11,14-eicosatetraenoic acid

A

prostaglandin D2
41598-07-6

prostaglandin D2

B

dinoprostone
363-24-6

dinoprostone

C

dinoprost
551-11-1

dinoprost

D

12-hydroxy-heptadecatrienoic acid

12-hydroxy-heptadecatrienoic acid

Conditions
ConditionsYield
With HUV-EC-C at 37℃; for 0.166667h; Enzyme kinetics; Further Variations:; Reagents; Cyclization; Enzymatic reaction;
(Z)-7-{(1R,2R,3R,5S)-3-(tert-Butyl-dimethyl-silanyloxy)-2-[(E)-(S)-3-(tert-butyl-dimethyl-silanyloxy)-oct-1-enyl]-5-hydroxy-cyclopentyl}-hept-5-enoic acid

(Z)-7-{(1R,2R,3R,5S)-3-(tert-Butyl-dimethyl-silanyloxy)-2-[(E)-(S)-3-(tert-butyl-dimethyl-silanyloxy)-oct-1-enyl]-5-hydroxy-cyclopentyl}-hept-5-enoic acid

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
With hydrogenchloride In tetrahydrofuran for 48h;
(Z)-7-{(1R,2R,3R,5S)-3-(tert-Butyl-dimethyl-silanyloxy)-5-hydroxy-2-[(E)-(S)-3-(1-methyl-1-trimethylsilanyl-ethoxy)-oct-1-enyl]-cyclopentyl}-hept-5-enoic acid

(Z)-7-{(1R,2R,3R,5S)-3-(tert-Butyl-dimethyl-silanyloxy)-5-hydroxy-2-[(E)-(S)-3-(1-methyl-1-trimethylsilanyl-ethoxy)-oct-1-enyl]-cyclopentyl}-hept-5-enoic acid

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
With hydrogenchloride
Prostaglandin G2
51982-36-6

Prostaglandin G2

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
With 4-methylaminoantirypine
(-)-7α-hydroxy-6β-(3α-hydroxy-1E-octenyl)-cis-2-oxabicyclo<3.3.0>octan-3-one
26054-67-1

(-)-7α-hydroxy-6β-(3α-hydroxy-1E-octenyl)-cis-2-oxabicyclo<3.3.0>octan-3-one

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 90 percent / pyridine / 3 h / Ambient temperature
2: 0.27 g / i-Bu2AlH / CH2Cl2 / 1 h / -78 °C
View Scheme
Multi-step reaction with 2 steps
1.1: diisobutylaluminium hydride / tetrahydrofuran; toluene / 0.5 h / -70 - -65 °C / Inert atmosphere
2.1: potassium tert-butylate / tetrahydrofuran / 0.67 h / 0 - 5 °C / Inert atmosphere
2.2: 1 h / 20 °C
View Scheme
Multi-step reaction with 2 steps
1.1: diisobutylaluminium hydride / dichloromethane / 2 h / -78 °C
2.1: potassium tert-butylate / tetrahydrofuran / 0.67 h / 0 °C / Inert atmosphere
2.2: 2 h / 0 - 20 °C / Inert atmosphere
View Scheme
(-)-7α-trimethylsilyloxy-6β-(3α-trimethylsilyloxy-1E-octenyl)-cis-2-oxabicyclo<3.3.0>octan-3-one
131846-24-7

(-)-7α-trimethylsilyloxy-6β-(3α-trimethylsilyloxy-1E-octenyl)-cis-2-oxabicyclo<3.3.0>octan-3-one

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 0.27 g / i-Bu2AlH / CH2Cl2 / 1 h / -78 °C
View Scheme
(S)-tert-butyl-dimethyl(oct-1-en-3-yloxy)silane
163877-58-5

(S)-tert-butyl-dimethyl(oct-1-en-3-yloxy)silane

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: second generation Grubb's catalyst / CH2Cl2 / 12 h / 40 °C
2: DIBAL-H / -78 °C
3: HCl
View Scheme
Multi-step reaction with 3 steps
1.1: Hoveyda-Grubbs catalyst second generation / 1,2-dichloro-ethane / 12 h / Inert atmosphere; Reflux
2.1: potassium tert-butylate / tetrahydrofuran / 0.67 h / 0 °C / Inert atmosphere
2.2: 0.5 h / 0 °C / Inert atmosphere
3.1: hydrogenchloride / water; acetone / 0.33 h / 20 °C / Inert atmosphere
View Scheme
(3aR,4R,5R,6aS)-5-(tert-butyldimethylsilyloxy)-4-vinylhexahydro-2H-cyclopenta[b]furan-2-one
906000-82-6

(3aR,4R,5R,6aS)-5-(tert-butyldimethylsilyloxy)-4-vinylhexahydro-2H-cyclopenta[b]furan-2-one

dinoprost
551-11-1

dinoprost

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: second generation Grubb's catalyst / CH2Cl2 / 12 h / 40 °C
2: DIBAL-H / -78 °C
3: HCl
View Scheme
Multi-step reaction with 4 steps
1: 84 percent / Grubbs' 2nd generation catalyst / CH2Cl2 / 12 h / 40 °C
2: DIBAL-H / CH2Cl2 / -78 °C
3: KOtBu / tetrahydrofuran
4: HCl / tetrahydrofuran / 48 h
View Scheme

551-11-1Upstream product

551-11-1Relevant articles and documents

NEW PROSTAGLANDIN (PGF) DERIVATIVES FROM THE SOFT CORAL LOBOPHYTON DEPRESSUM

Carmely, S.,Kashman, Y.,Loya, Y.,Benayahu, Y.

, p. 875 - 878 (1980)

Four PGF derivatives (15S)-PGF2α-11-acetate methyl ester (1a), the 18-acetoxy derivative of compound 1a (2a) as well as their two corresponding free carboxylic acids (1b and 2b) were isolated from a soft-coral and their structure elucidated, mainly on basis of their spectral data.

Concise, scalable and enantioselective total synthesis of prostaglandins

Zhang, Fuhao,Zeng, Jingwen,Gao, Mohan,Wang, Linzhou,Chen, Gen-Qiang,Lu, Yixin,Zhang, Xumu

, p. 692 - 697 (2021/06/01)

Prostaglandins are among the most important natural isolates owing to their broad range of bioactivities and unique structures. However, current methods for the synthesis of prostaglandins suffer from low yields and lengthy steps. Here, we report a practicability-oriented synthetic strategy for the enantioselective and divergent synthesis of prostaglandins. In this approach, the multiply substituted five-membered rings in prostaglandins were constructed via the key enyne cycloisomerization with excellent selectivity (>20:1 d.r., 98% e.e.). The crucial chiral centre on the scaffold of the prostaglandins was installed using the asymmetric hydrogenation method (up to 98% yield and 98% e.e.). From our versatile common intermediates, a series of prostaglandins and related drugs could be produced in two steps, and fluprostenol could be prepared on a 20-gram scale. [Figure not available: see fulltext.]

Access to a Key Building Block for the Prostaglandin Family via Stereocontrolled Organocatalytic Baeyer–Villiger Oxidation

Zhu, Kejie,Hu, Sha,Liu, Minjie,Peng, Haihui,Chen, Fen-Er

, p. 9923 - 9927 (2019/05/16)

A new protocol for the construction of a crucial bicyclic lactone of prostaglandins using a stereocontrolled organocatalytic Baeyer–Villiger (B-V) oxidation was developed. The key B-V oxidation of a racemic cyclobutanone derivative with aqueous hydrogen peroxide has enabled an early-stage construction of a bicyclic lactone skeleton in high enantiomeric excess (up to 95 %). The generated bicyclic lactone is fully primed with two desired stereocenters and enabled the synthesis of the entire family of prostaglandins according to Corey′s route. Furthermore, the reactivity and enantioselectivity of B-V oxidation of racemic bicyclic cyclobutanones were evaluated and 90–99 % ee was obtained, representing one of the most efficient routes to chiral lactones. This study further facilitates the synthesis of prostaglandins and chiral lactone-containing natural products to promote drug discovery.

Total synthesis of PGF2α and 6,15-diketo-PGF1α and formal synthesis of 6-keto-PGF1α via three-component coupling

Kim, Taehyeong,Lee, Sung Il,Kim, Sejin,Shim, Su Yong,Ryu, Do Hyun

, (2019/09/17)

The asymmetric total synthesis of PGF2α and 6,15-diketo-PGF1α and formal synthesis of 6-keto-PGF1α from a common key intermediate are described. The key intermediate, which has a chiral cyclopentane backbone possessing suitable functional groups with required stereochemistry for both side chains, was prepared from (R)-4-silyloxy-2-cyclopentenone through a three-component coupling reaction. The Wittig reaction, Nozaki-Hiyama-Kishi (NHK) coupling and cross metathesis completed the synthesis of PGF2α, 6,15-diketo-PGF1α and 6-keto-PGF1α.

METHOD OF MAKING A CROSS METATHESIS PRODUCT

-

Paragraph 00122; 00123; 00124; 00125, (2019/02/06)

Method of making a cross metathesis product, the method comprising at least step (X) or step (Y): (X) reacting in a cross metathesis reaction a first compound comprising a terminal olefinic group with a second compound comprising a terminal olefinic group, wherein the first and the second compound may be identical or may be different from one another; or (Y) reacting in a ring-closing metathesis reaction two terminal olefinic groups which are comprised in a third compound; wherein the reacting in step (X) or step (Y) is performed in the presence of a ruthenium carbene complex comprising a [Ru=C]-moiety and an internal olefin.

Of the trometamol prostaglandin F2 α synthesis method (by machine translation)

-

, (2017/08/30)

The invention discloses a of the trometamol prostaglandin F2 α synthesis method, as the compound (-) - Corey lactone diol as raw materials, through the oxidation reaction to obtain lactone aldehyde, lactone aldehydechain after the weidiWeidi Greecehuo Naer reaction with - the lower side of the splicing an olefin, the olefin double-carbonyl after reduction to obtain the alcohol, with puncture ylide - wittich reaction the upper side of the obtained prostaglandin F2 α, then the prostaglandin F2 α of the trometamol after crystallization by dissolving of the trometamol prostaglandin F2 α. The synthesis method, without noble metal catalyst, there is little side reaction, high yield, low cost, less pollution, is suitable for industrial production. (by machine translation)

In Situ Methylene Capping: A General Strategy for Efficient Stereoretentive Catalytic Olefin Metathesis. the Concept, Methodological Implications, and Applications to Synthesis of Biologically Active Compounds

Xu, Chaofan,Shen, Xiao,Hoveyda, Amir H.

, p. 10919 - 10928 (2017/08/15)

In situ methylene capping is introduced as a practical and broadly applicable strategy that can expand the scope of catalyst-controlled stereoselective olefin metathesis considerably. By incorporation of commercially available Z-butene together with robust and readily accessible Ru-based dithiolate catalysts developed in these laboratories, a large variety of transformations can be made to proceed with terminal alkenes, without the need for a priori synthesis of a stereochemically defined disubstituted olefin. Reactions thus proceed with significantly higher efficiency and Z selectivity as compared to when other Ru-, Mo-, or W-based complexes are utilized. Cross-metathesis with olefins that contain a carboxylic acid, an aldehyde, an allylic alcohol, an aryl olefin, an α substituent, or amino acid residues was carried out to generate the desired products in 47-88% yield and 90:10 to >98:2 Z:E selectivity. Transformations were equally efficient and stereoselective with a ~70:30 Z-:E-butene mixture, which is a byproduct of crude oil cracking. The in situ methylene capping strategy was used with the same Ru catechothiolate complex (no catalyst modification necessary) to perform ring-closing metathesis reactions, generating 14- to 21-membered ring macrocyclic alkenes in 40-70% yield and 96:4-98:2 Z:E selectivity; here too, reactions were more efficient and Z-selective than when the other catalyst classes are employed. The utility of the approach is highlighted by applications to efficient and stereoselective syntheses of several biologically active molecules. This includes a platelet aggregate inhibitor and two members of the prostaglandin family of compounds by catalytic cross-metathesis reactions, and a strained 14-membered ring stapled peptide by means of macrocyclic ring-closing metathesis. The approach presented herein is likely to have a notable effect on broadening the scope of olefin metathesis, as the stability of methylidene complexes is a generally debilitating issue with all types of catalyst systems. Illustrative examples of kinetically controlled E-selective cross-metathesis and macrocyclic ring-closing reactions, where E-butene serves as the methylene capping agent, are provided.

Decarboxylative alkenylation

Edwards, Jacob T.,Merchant, Rohan R.,McClymont, Kyle S.,Knouse, Kyle W.,Qin, Tian,Malins, Lara R.,Vokits, Benjamin,Shaw, Scott A.,Bao, Deng-Hui,Wei, Fu-Liang,Zhou, Ting,Eastgate, Martin D.,Baran, Phil S.

, p. 213 - 218 (2017/05/19)

Olefin chemistry, through pericyclic reactions, polymerizations, oxidations, or reductions, has an essential role in the manipulation of organic matter. Despite its importance, olefin synthesis still relies largely on chemistry introduced more than three decades ago, with metathesis being the most recent addition. Here we describe a simple method of accessing olefins with any substitution pattern or geometry from one of the most ubiquitous and variegated building blocks of chemistry: alkyl carboxylic acids. The activating principles used in amide-bond synthesis can therefore be used, with nickel- or iron-based catalysis, to extract carbon dioxide from a carboxylic acid and economically replace it with an organozinc-derived olefin on a molar scale. We prepare more than 60 olefins across a range of substrate classes, and the ability to simplify retrosynthetic analysis is exemplified with the preparation of 16 different natural products across 10 different families.

Synthesis of Alfaprostol and PGF2α through 1,4-Addition of an Alkyne to an Enal Intermediate as the Key Step

Baars, Hannah,Classen, Moritz J.,Aggarwal, Varinder K.

, p. 6008 - 6011 (2017/11/10)

The veterinary drug Alfaprostol and prostaglandin PGF2α have been synthesized in just nine steps. The strategy involved the conjugate addition of an alkyne to a bicyclic enal, available in three steps by a proline-catalyzed aldol reaction of succinaldehyde. In the case of Alfaprostol, this resulted in the shortest synthesis reported to date. For PGF2α, this approach improved our previous route by making the 1,4-addition and ozonolysis more operationally simple.

Rh(I)-Catalyzed 1,4-Conjugate Addition of Alkenylboronic Acids to a Cyclopentenone Useful for the Synthesis of Prostaglandins

Syu, Jin-Fong,Wang, Yun-Ting,Liu, Kung-Cheng,Wu, Ping-Yu,Henschke, Julian P.,Wu, Hsyueh-Liang

, p. 10832 - 10844 (2016/11/29)

An efficient and trans-diastereoselective Rh(I)-catalyzed 1,4-conjugate addition reaction of alkenylboronic acids and a homochiral (R)-4-silyloxycyclopentenone useful for the synthesis of derivatives of prostaglandins E and F is described for the first time. The reaction functions under mild conditions and is particularly rapid (≤6 h) under low power (50 W) microwave irradiation at 30 °C in MeOH in the presence of a catalytic amount of KOH. Under these conditions, 3 mol % of [RhCl(COD)]2 is typically required to produce high yields. The method also functions without microwave irradiation at 3 °C in the presence of a stoichiometric amount of KOH. Under these conditions, only 1.5 mol % of [RhCl(COD)]2 is needed, but the reaction is considerably slower. The method accepts a range of aryl- and alkyl-substituted alkenylboronic acids, and its utility has been demonstrated by the synthesis of PGF2α (dinoprost) and tafluprost.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 551-11-1